Phase 3 open label safety study of ADS-5102

Trial Profile

Phase 3 open label safety study of ADS-5102

Phase of Trial: Phase III

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Amantadine (Primary)
  • Indications Movement disorders
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top